Japan’s largest drugmaker Takeda Pharmaceutical (TYO: 4502) has entered into an agreement with US drugmaker AMAG Pharmaceuticals (Nasdaq: AMAG) to mutually terminate the March 2010 license, development and commercialization agreement for ferumoxytol in ex-USA territories.
Under that accord, worth a potential $280 million to AMAG, Takeda was granted rights to market ferumoxytol in Canada, the European Union and Switzerland, as well as certain other geographic territories (under the trade name Rienso outside of Canada where the product's trade name is Feraheme).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze